Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Vertex Pharmaceuticals and GlaxoSmithKline (GSK) have signed a non-exclusive agreement for Phase 2 all-oral hepatitis C study of VX-135 and GSK2336805.
Subscribe to our email newsletter
The companies will jointly fund the study that is expected to begin in 2013.
Phase 2 proof-of-concept study is designed to estimate the safety profile, tolerability profile and viral cure rates of 12-week combination of VX-135 and GSK2336805.
Vertex senior vice president and chief medical officer Robert Kauffman said the agreement underscores the company’s commitment to develop all-oral treatment regimens for people with hepatitis C using medicines within our own pipeline and by working in collaboration with other companies like GSK.
"We are focused on the development of new all-oral treatments for hepatitis C that have the potential to provide a high cure rate with only 12 weeks of treatment, and we look forward to the start of this study with GSK," Kauffman added.
Vertex’s uridine nucleotide analogue pro-drug VX-135, is designed to target the NS5B polymerase thereby restraining hepatitis C viral replication.
GSK is developing GSK2336805 as an investigational NS5A replication complex inhibitor to treat hepatitis C.